+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oragenics Inc (OGEN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 45 Pages
  • June 2023
  • GlobalData
  • ID: 4302704
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Oragenics Inc (OGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oragenics Inc (Oragenics) focuses on designing of TerraCoV2, immunization product candidate to fight the novel coronavirus. The company is also focused on the development and commercialization of novel antibiotics against infectious diseases, other treatments for oral mucositis and healthcare-associated infections (HAIs). The company's product candidates include OG716, an antibiotic candidate for treating the HAIs; SMaRT Replacement Therapy, a painless treatment to prevent tooth decay; and LPT3-04, a naturally occurring chemical agent that promotes weight loss. It develops product candidates based on the mechanism action of Lantibiotics. The company has collaborations with National Institute of Allergy and Infectious Diseases, Adjuvance Technologies Inc, Precigen Inc, LPThera LLC and Aragen Bioscience for the development of its pipeline products. Oragenics is headquartered in Tampa, Florida, the US.

Oragenics Inc Key Recent Developments

  • Mar 14, 2023: Oragenics announces positive results in several lantibiotics compounds against MRSA and VRE
  • Mar 08, 2023: Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
  • Mar 02, 2023: Oragenics and Inspirevax sign agreement for Covid-19 vaccine development
  • Dec 16, 2022: Oragenics announces management changes

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Oragenics Inc - Key Facts
  • Oragenics Inc - Key Employees
  • Oragenics Inc - Key Employee Biographies
  • Oragenics Inc - Major Products and Services
  • Oragenics Inc - History
  • Oragenics Inc - Company Statement
  • Oragenics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Oragenics Inc - Business Description
  • R&D Overview
  • Oragenics Inc - Corporate Strategy
  • Oragenics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Oragenics Inc - Strengths
  • Oragenics Inc - Weaknesses
  • Oragenics Inc - Opportunities
  • Oragenics Inc - Threats
  • Oragenics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Oragenics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 14, 2023: Oragenics announces positive results in several lantibiotics compounds against MRSA and VRE
  • Mar 08, 2023: Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
  • Mar 02, 2023: Oragenics and Inspirevax sign agreement for Covid-19 vaccine development
  • Dec 16, 2022: Oragenics announces management changes
  • Sep 15, 2022: Oragenics Announces Annual Meeting of Shareholders
  • Aug 09, 2022: Oragenics announce quarter ended June 30, 2022
  • Jun 23, 2022: Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
  • Jan 26, 2022: Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Oragenics Inc, Key Facts
  • Oragenics Inc, Key Employees
  • Oragenics Inc, Key Employee Biographies
  • Oragenics Inc, Major Products and Services
  • Oragenics Inc, History
  • Oragenics Inc, Other Locations
  • Oragenics Inc, Subsidiaries
  • Oragenics Inc, Key Competitors
  • Oragenics Inc, Ratios based on current share price
  • Oragenics Inc, Annual Ratios
  • Oragenics Inc, Interim Ratios
  • Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Oragenics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Oragenics Inc, Performance Chart (2018 - 2022)
  • Oragenics Inc, Ratio Charts
  • Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Assembly Biosciences Inc
  • AstraZeneca Plc
  • Johnson & Johnson
  • Moderna Inc
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Seres Therapeutics Inc
  • Theriva Biologics Inc